PHARVARIS NV (PHVS:NASDAQ)
$30.14 1.16 (4.0028%)
Analysed PHARVARIS NV (PHVS:NASDAQ) News Sources
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
20-04-2026
yahoo.com
KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too
29-04-2026
yahoo.com
For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next
30-04-2026
fool.com
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
08-05-2026
yahoo.com
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
11-05-2026
yahoo.com
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000
11-05-2026
fool.com
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
12-05-2026
yahoo.com
Pharvaris Equity Raise Supports Late Stage HAE Push And Valuation Case
14-05-2026
yahoo.com
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
19-05-2026
fool.com
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
29-05-2026
yahoo.com
What is the current price of PHARVARIS NV (PHVS:NASDAQ)?
The current price of PHARVARIS NV (PHVS:NASDAQ) is $30.14.
PHARVARIS NV (PHVS:NASDAQ) absolute price change since previous trading day?
The absolute price change of PHARVARIS NV (PHVS:NASDAQ) since the previous trading day is $1.16.
PHARVARIS NV (PHVS:NASDAQ) percentage price change since previous trading day?
The percentage price change of PHARVARIS NV (PHVS:NASDAQ) since the previous trading day is 4.0028%.
What is the most recent average sentiment score for PHARVARIS NV (PHVS:NASDAQ)?
The most recent average sentiment score for PHARVARIS NV (PHVS:NASDAQ) is 74 out of 100.
What is the most recent average sentiment for PHARVARIS NV (PHVS:NASDAQ)?
The most recent sentiment for PHARVARIS NV (PHVS:NASDAQ) is .
SEC-8K** Filing Available For PHARVARIS NV (PHVS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.